Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Jingyi He, Zhengrong Huang, Linzhi Han, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 5
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 142
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 101
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
Ha Yeong Choi, Ji‐Eun Chang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13618-13618
Open Access | Times Cited: 46
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 64
An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Khalid Saad Alharbi, Mohammad Arshad Javed Shaikh, Obaid Afzal, et al.
Chemico-Biological Interactions (2022) Vol. 366, pp. 110108-110108
Closed Access | Times Cited: 42
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, et al.
Oncology Letters (2022) Vol. 24, Iss. 5
Open Access | Times Cited: 41
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Sushanta Halder, Soumi Basu, Shobhit P. Lall, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 4-5, pp. 305-324
Open Access | Times Cited: 40
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Zhinan Cheng, Hongwei Cui, Yaqi Wang, et al.
Oncology Reports (2023) Vol. 51, Iss. 1
Open Access | Times Cited: 26
Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer
Fushi Han, Shuzhen Chen, Kangwei Zhang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
Bethany D. Latham, Raeanne M. Geffert, Klarissa D. Jackson
Drug Metabolism and Disposition (2024) Vol. 52, Iss. 6, pp. 479-492
Open Access | Times Cited: 8
The emerging landscape and future perspective of SCLC transformation: from molecular mechanisms to therapeutic strategies
Chenyue Zhang, Kai Wang, Haiyong Wang
Critical Reviews in Oncology/Hematology (2025) Vol. 207, pp. 104616-104616
Closed Access | Times Cited: 1
Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
Y. Tang, Jianfang Xu, Qingle Chen, et al.
Clinical Case Reports (2025) Vol. 13, Iss. 2
Open Access | Times Cited: 1
Immunotherapy efficacy between exon 19 deletion and exon 21 L858R mutation in advanced EGFR mutant non-small-cell lung cancer: a direct and indirect meta-analysis
Zihong Chen, Lanlan Pang, Yang Yuwen, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 2, pp. 422-430
Open Access | Times Cited: 1
Metal-organic coordinated self-assembled nanomedicine for enhanced cuproptosis-mediated chemo-photo-chemodynamic synergistic therapy of non-small cell lung cancer
R.P. Liu, Ruirui Zhao, Zi-Wei Yu, et al.
Chemical Engineering Journal (2025), pp. 161305-161305
Closed Access | Times Cited: 1
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model
Nadeem Moghal, Quan Li, Erin Stewart, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 4, pp. 499-515
Open Access | Times Cited: 29
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
Lian Yu, Yaohua Hu, Jianlin Xu, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 3, pp. 635-643
Closed Access | Times Cited: 19
Single-cell gene set enrichment analysis and transfer learning for functional annotation of scRNA-seq data
Melania Franchini, Simona Pellecchia, Gaetano Viscido, et al.
NAR Genomics and Bioinformatics (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 18
Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, et al.
European Journal of Cancer (2023) Vol. 189, pp. 112919-112919
Open Access | Times Cited: 18
A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy
Bin Xu, Fanjun Zeng, Jialong Deng, et al.
Bioactive Materials (2023) Vol. 27, pp. 337-347
Open Access | Times Cited: 17
The m6A methyltransferase RBM15 affects tumor cell stemness and progression of cervical cancer by regulating the stability of lncRNA HEIH
Yi Quan, Muchuan Zhou, Jinhong Li, et al.
Experimental Cell Research (2024) Vol. 436, Iss. 2, pp. 113924-113924
Closed Access | Times Cited: 6
Targeted therapeutic options in early and metastatic NSCLC-overview
Gabriella Gálffy, Éva Morócz, Réka Korompay, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 6
Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer
Simona Pellecchia, Melania Franchini, Gaetano Viscido, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Yajun Liu, Chenyao Li, Hongwei Liu, et al.
Archives of Pharmacal Research (2024) Vol. 47, Iss. 5, pp. 442-464
Closed Access | Times Cited: 6
EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer
Cheng Yang, Shuxiang Ma, Jie Zhang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 23
Open Access | Times Cited: 6
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Jia Zhong, Hua Bai, Zhijie Wang, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 1, pp. 18-42
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top